Traphagen Investment Advisors 13F: Exits UnitedHealth (UNH) Stake

Traphagen Investment Advisors has completely parted ways with its holdings in UnitedHealth Group Incorporated (NYSE: UNH). According to a Form 13F filing with the Securities and Exchange Commission on October 14, 2026, the firm sold its entire stake of 48shares. Because 13F reports look backward at portfolio activity from previous periods, this filing shows the fund's status at that time and might not reflect where things stand today.

Inside Traphagen Investment Advisors's UnitedHealth Trade

The fund officially closed out its position by selling all 483 shares it held previously. This complete exit brought the share count down to zero with a 100.0% reduction. Investors should note that 13F filings only capture portfolio snapshots at the close of a quarter, meaning actual trades could have happened weeks before the disclosure date.

Other Institutional Activity in UnitedHealth

Other large institutional players made substantial moves in UnitedHealth Group ahead of the filing. Blackrock Inc. grew its holdings by 3,394,259 shares, ending with 76,863,061 shares worth about $30,855,138,014.0. Vanguard Capital Management LLC added 441,525 shares, growing its stake by 0.8% to 59,311,525 shares valued at roughly $23,809,425,046.0. State Street Corporation increased its holdings by 299,205 shares, finishing with 45,633,267 shares worth about $18,318,562,037.0 after a 0.7% change. Capital World Investors boosted its position by 2,103,297 shares, lifting its stake 7.6% to 29,887,932 shares valued near $11,997,912,323.0. FMR, LLC made a much larger splash by adding 15,974,192 shares, which pushed its holdings up 132.9% to 27,992,995 shares worth about $11,237,227,777.0.

UnitedHealth Group Incorporated Stock Up 1.8%

UnitedHealth shares recently traded around $402.70. The stock is currently sitting 4.0% above its 50-day moving average of $387.35 and 12.3% above its 200-day moving average of $358.75. Even with those gains, the shares remain about 12.8% below their 52-week high of $461.62 while resting 57.3% above their 52-week low of $255.97.

Recent Earnings

UnitedHealth reported trailing-twelve-month revenue of $450,059,010,048.0 alongside a trailing EPS of $15.55. The company's net profit margin sits at 3.5%, paired with a return on equity of 15.8%. The next round of earnings is expected on January 26, 2027.

Dividend

Shareholders collect an annual dividend yield of 2.28%, supported by a payout ratio of 57.6%.

Insider Buying and Selling at UnitedHealth Group Incorporated

Company insiders also transacted in company stock prior to the filing. Officer Patrick Hugh Conway sold 500 shares on August 5, 2026, at an average price of $410.00 for a total value of $205,000.0. Later on August 21, 2026, Conway sold another 1,169 shares at $390.00 apiece, totaling $455,910.0.

Analysts Set New Price Targets

Wall Street firms adjusted their views on UnitedHealth around the filing window. On July 21, 2026, JP Morgan maintained its Overweight rating and raised its target from $466.00 to $516.00. TD Cowen maintained a Hold rating on October 9, 2026, lowering its target from $430.00 to $402.00. On October 14, 2026, Piper Sandler maintained its Overweight rating with a target moving from $502.00 to $504.00. Barclays also maintained an Overweight rating on October 14, 2026, nudging its target from $441.00 down to $440.00. Baird maintained a Neutral rating on October 14, 2026, dropping its target from $453.00 to $427.00. Across the broader analyst community, the stock carries a consensus buy recommendation from 25 opinions with a mean price target of $477.04.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a major healthcare and insurance provider in the United States and abroad. The enterprise runs through several segments, including Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, offering care delivery, pharmacy services, and medical benefits management.

Bottom Line

Institutional adjustments like this complete exit offer a look at past portfolio shifts rather than real-time trading decisions. Observers will want to watch the company's upcoming earnings report in January 2027 and subsequent SEC filings to see how institutional appetite for the stock evolves. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.